Imiquimod for anogenital warts in non-immunocompromised adults

  • Protocol
  • Intervention

Authors

  • Carlos F Grillo-Ardila,

    Corresponding author
    1. National University of Colombia, Department of Obstetrics & Gynecologic and Clinical Research Institute, Bogota, Colombia
    • Carlos F Grillo-Ardila, Department of Obstetrics & Gynecologic and Clinical Research Institute, National University of Colombia, Carrera 30 No 45-03, Bogota, Colombia. cfgrilloa@unal.edu.co.

    Search for more papers by this author
  • Hernando G Gaitán,

    1. National University of Colombia, Department of Obstetrics & Gynecology and Clinical Research Institute, Faculty of Medicine, Bogota, Colombia
    Search for more papers by this author
  • Edith Angel-Müller,

    1. National University of Colombia, Department of Obstetrics & Gynecology, Bogota, Colombia
    Search for more papers by this author
  • Ariel I Ruiz-Parra,

    1. National University of Colombia, Department of Obstetrics & Gynecology and Clinical Research Institute, Faculty of Medicine, Bogota, Colombia
    Search for more papers by this author
  • Anne Lethaby

    1. University of Auckland, Obstetrics and Gynaecology, Auckland, New Zealand
    Search for more papers by this author

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the effectiveness and safety of imiquimod for the treatment of anogenital warts in non-immunocompromised adults.

Ancillary